Protalix BioTherapeutics, Inc. (NYSE:PLX) Shares Acquired by Northern Trust Corp

Northern Trust Corp lifted its stake in Protalix BioTherapeutics, Inc. (NYSE:PLX - Free Report) by 1,299.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 731,742 shares of the company's stock after acquiring an additional 679,451 shares during the quarter. Northern Trust Corp owned 0.99% of Protalix BioTherapeutics worth $1,376,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Y Intercept Hong Kong Ltd acquired a new position in shares of Protalix BioTherapeutics in the 4th quarter worth approximately $35,000. PFG Investments LLC acquired a new position in shares of Protalix BioTherapeutics in the 4th quarter worth approximately $39,000. Prudential Financial Inc. acquired a new position in shares of Protalix BioTherapeutics in the 4th quarter worth approximately $68,000. Marshall Wace LLP acquired a new stake in Protalix BioTherapeutics during the 4th quarter worth approximately $192,000. Finally, Renaissance Technologies LLC lifted its holdings in Protalix BioTherapeutics by 17.0% during the 4th quarter. Renaissance Technologies LLC now owns 1,118,000 shares of the company's stock worth $2,102,000 after buying an additional 162,100 shares in the last quarter. 16.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have issued reports on PLX. Wall Street Zen lowered shares of Protalix BioTherapeutics from a "strong-buy" rating to a "buy" rating in a report on Monday, May 12th. HC Wainwright increased their target price on shares of Protalix BioTherapeutics from $10.00 to $15.00 and gave the stock a "buy" rating in a report on Monday, February 3rd.

Protalix BioTherapeutics Stock Down 2.5%

Protalix BioTherapeutics stock traded down $0.04 during mid-day trading on Friday, reaching $1.55. 465,353 shares of the company's stock were exchanged, compared to its average volume of 545,577. The company has a market cap of $123.39 million, a P/E ratio of -11.92 and a beta of -0.05. Protalix BioTherapeutics, Inc. has a twelve month low of $0.82 and a twelve month high of $3.10. The company has a fifty day moving average of $2.32 and a 200-day moving average of $2.19.

Protalix BioTherapeutics (NYSE:PLX - Get Free Report) last released its earnings results on Friday, May 9th. The company reported ($0.05) earnings per share (EPS) for the quarter. Protalix BioTherapeutics had a negative return on equity of 30.89% and a negative net margin of 21.03%. Equities research analysts expect that Protalix BioTherapeutics, Inc. will post 0.01 earnings per share for the current fiscal year.

Protalix BioTherapeutics Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.